Brief: InflaRx Reports Additional Analysis Of The SHINE Phase IIb Results For IFX-1 In Hidradenitis Suppurativa

Inflarx NV

18/07/2019 21:49

July 18 (Reuters) - Inflarx NV  IF0G.F :
    * INFLARX REPORTS ADDITIONAL ANALYSIS OF THE SHINE PHASE IIB
RESULTS FOR IFX-1 IN HIDRADENITIS SUPPURATIVA
    * INFLARX NV - IFX-1 TREATMENT IN HIGH DOSE GROUP RESULTED
IN
MULTIPLE EFFICACY SIGNALS SUPPORTING FURTHER DEVELOPMENT OF
IFX-1 IN HS
    * INFLARX NV - IFX-1 SUPPRESSED C5A LEVELS DOSE DEPENDENTLY
AND
EXHIBITED A FAVORABLE SAFETY PROFILE WITH LOW ANTI-DRUG ANTIBODY
RATES
    * INFLARX NV - OPEN-LABEL EXTENSION STUDY IS ONGOING,
INFLARX
PLANS END OF PHASE II REGULATORY DISCUSSIONS AFTER COMPLETION OF
SHINE TRIAL

Source text for Eikon:  ID:nGNX3yC1Xy 
Further company coverage:  IF0G.F 

 (Reuters.Briefs@thomsonreuters.com)